Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer

NCT01776008 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

16

Enrollment

NIH

Sponsor class

Stopped Study did not pass Stage 1 interim analysis.

Conditions

Estrogen Receptor Positive
HER2/Neu Negative
Recurrent Breast Carcinoma
Stage IIA Breast Cancer
Stage IIB Breast Cancer
Stage IIIA Breast Cancer
Stage IIIB Breast Cancer
Stage IIIC Breast Cancer

Interventions

DRUG: Akt Inhibitor MK2206
DRUG: Anastrozole
DRUG: Goserelin Acetate
OTHER: Laboratory Biomarker Analysis
PROCEDURE: Neoadjuvant Therapy
OTHER: Pharmacological Study
PROCEDURE: Therapeutic Conventional Surgery

Sponsor

National Cancer Institute (NCI)